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Background-—The incidence and predictors of bleeding after acute coronary syndrome are unclear within the real-world setting.
Our objective was to determine the incidence, types, timing, and predictors of bleeding complications following hospital discharge
after acute coronary syndrome.
Methods and Results-—We used the Clinical Practice Research Datalink, with linkage to Hospital Episode Statistics, to determine
the incidence, timing, and types of bleeding events within 12 months after hospital discharge for acute coronary syndrome. We
assessed independent associations between postdischarge bleeding and baseline patient characteristics using a competing risk
regression model, accounting for death as a competing event. Among 27 660 patients surviving to hospital discharge, 3620 (13%)
experienced bleeding complications at a median time of 123 days (interquartile range, 45–223 days) after discharge. The
incidence of bleeding was 162/1000 person-years (95% CI, 157–167/1000 person-years) within the ﬁrst 12 months after hospital
discharge. Bruising (949 bleeds [26%]) was the most common type of ﬁrst bleeding event, followed by gastrointestinal bleed (705
bleeds [20%]), whereas intracranial bleed was relatively rare (81 bleeds [2%]). Signiﬁcant predictors of postdischarge bleeding
included history of bleeding complication, oral anticoagulant prescription, history of peripheral vascular disease, chronic
obstructive pulmonary disease, and advanced age (>80 years). Predictors for postdischarge bleeding varied, depending on the
anatomic site of the bleeding event.
Conclusions-—Bleeding complications after hospital discharge for acute coronary syndrome are common. Patients who experience
these bleeding events have distinct baseline characteristics, which vary by anatomic site of the bleed. These characteristics can
inform risk-beneﬁt considerations in deciding on favorable combination and duration of secondary antithrombotic therapy. ( J Am
Heart Assoc. 2019;8:e013679. DOI: 10.1161/JAHA.119.013679.)
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T he management of acute coronary syndrome (ACS) withantithrombotic medications achieves the desired goal of
reducing the risk of future ischemic events. But these
reductions are accompanied by bleeding complications.1
In clinical trials, the incidence of major bleeding compli-
cations is reported to be between 1% and 10%, depending on
the bleeding deﬁnition used,2–4 with observational studies
reporting incidences of between 2.8%5 and 11%.6 However,
the emphasis in most of these studies has been on major in-
hospital or 30-day bleeding events (a composite of in-hospital
and postdischarge events), with little consideration for events
in the longer term after hospital discharge. After hospital
discharge, patients with ACS often remain on dual antiplatelet
therapy for up to a year, and aspirin indeﬁnitely, so their risk
of bleeding complications persists in the longer term.7
Major in-hospital bleeding has been associated with
sociodemographic characteristics, cardiovascular and noncar-
diovascular comorbidities, and pharmacological and procedu-
ral characteristics,8–10 leading to the development of risk
scoring algorithms that stratify patients into risk proﬁles for
these bleeding events.8–10 However, it is unclear whether
these characteristics are also predictive of bleeding events
after hospital discharge. For example, procedural character-
istics may become less relevant in predicting the risk of
postdischarge bleeding events, whereas patient
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characteristics and pharmacological choice may become
more important after discharge. The few studies that have
reported on characteristics associated with postdischarge
bleeding events have mostly been randomized controlled
trials,11–13 where minor bleeding events, high-risk multimor-
bid “real-world” patients, and those receiving long-term oral
anticoagulation (a potential risk factor for bleeding) have been
excluded. Therefore, the generalizability of these studies to
the wider population with ACS in the real-world setting is
unclear.
While the nature of in-hospital bleeds and their predictors
have been well described,8–10,14 the incidence, types, and
predictors of bleeding events that occur after hospital
discharge are unclear. The ﬁrst objective of this study was
to determine the incidence, timing, and types of bleeding
events within 12 months after hospital discharge. The second
objective was to determine the predictors of bleeding events
and site-speciﬁc bleeds after hospital discharge.
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Study Design and Setting
This was a cohort study set within the Clinical Practice
Research Datalink (CPRD),15 with linkage to Hospital Episode
Statistics (HES) and Ofﬁce for National Statistics mortality
data. CPRD is a primary care electronic healthcare record
database containing anonymized routinely collected consul-
tation records from >670 general practices in the United
Kingdom. The CPRD population is representative of the UK
population on age, sex, and ethnicity.15 Practices included in
our analysis (n=377, all from England) had to have linked HES
and Ofﬁce for National Statistics mortality data. Practices
with and without such linkage are similar in respect of
demographic data, years of follow-up, and prescribing.16 The
CPRD data set is described further in Data S1. HES is a
secondary care database containing detailed information on
diagnosis, procedures, admissions, and discharge dates from
National Health Service hospitals or hospitals where the cost
of care is reimbursed by the National Health Service. The
National Health Service is the main healthcare provider in the
United Kingdom that is free at the point of care. The Ofﬁce for
National Statistics mortality data contain records of date of
death and the underlying cause of death of all deceased
individuals in the United Kingdom. The validity of diagnoses
for conditions such as ACS is high in both CPRD and HES.17,18
The study was approved by the CPRD Independent Scientiﬁc
Advisory Committee (protocol No. 17_181). The requirement
for informed consent was waived because these databases
are anonymized following strict conﬁdentiality guidelines
before being distributed for research purposes.
Study Population
Patients were included in the study if they were aged
≥18 years, with a primary care record for ACS in CPRD
between 2006 and 2016 and a matching ACS record in HES
within 1 month of the primary care ACS event, but without a
primary care record of ACS in the preceding 2 years. The
period of 2 years was selected to identify only incident ACS
cases. The index date for each patient was the date of
hospital discharge after the matched ACS event in HES. Read
codes and International Classiﬁcation of Diseases, Tenth
Revision (ICD-10) code lists used in deﬁning ACS in CPRD
and HES are available at http://www.keele.ac.uk/mrr.
Patients were excluded if they did not survive to discharge,
they had no discharge date recorded in HES, or their ﬁrst ACS
event preceded the date their registered practice was deemed
to have up to standard data in CPRD.
Predictors
We identiﬁed potential predictors of bleeding by reviewing
previously published risk scores for in-hospital and postdis-
charge bleeding events,8–14,19–21 as well as studies that had
reported on characteristics associated with bleeding after
ACS.22–26 Nineteen potential predictors were selected for
inclusion in the study on the basis of clinical judgement.
Clinical Perspective
What Is New?
• Bleeds after hospital discharge for acute coronary syndrome
are common, with bruising and gastrointestinal bleeds the
most common.
• History of bleeding complications, chronic obstructive
pulmonary disease, peripheral vascular disease, manage-
ment with oral anticoagulants after hospital discharge, and
aged >80 years were the most signiﬁcant determinants of
postdischarge bleeding.
• Predictors for postdischarge bleeding varied, depending on
the anatomic site of the bleeding event.
What Are the Clinical Implications?
• These baseline predictors can assist clinicians in identifying
patients at risk of bleeding complications after hospital
discharge so that longer-term antithrombotic therapy can be
tailored to ﬁt an individual patient’s risk proﬁle.
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These predictors included sociodemographic characteristics,
cardiovascular and noncardiovascular comorbidities (recorded
in the previous 2 years before the index date, except body
mass index, which was deﬁned as last measurement until
30 days after index date to capture the most recent body
mass index for a patient), in-hospital procedures, and
pharmacological characteristics (recorded in the previous
6 months before the index date in the case of NSAIDs and
selective serotonin reuptake inhibitors, or within 90 days
after hospital discharge in the case of antithrombotic drugs).
See Table S1 for the full list of potential predictors and their
baseline deﬁnitions.
Bleeding End Point
The outcome of bleeding was deﬁned as having a diagnostic
record for bleeding in a patient primary care record or a death
record in Ofﬁce for National Statistics mortality data, with
bleeding as the underlying cause within 12 months after the
index date. Bleeding events included gastrointestinal bleed-
ing, hematemesis, melena, gastrointestinal ulcers with bleed-
ing, intracranial bleeding, hemoptysis, epistaxis, hemarthrosis,
hemopericardium, hematuria, vaginal bleeding, retinal bleed-
ing, anemia caused by blood loss, spontaneous bruising,
petechiae, spontaneous ecchymoses, and bleeding not else-
where classiﬁed. Bleeding events were further classiﬁed
based on site into bruising; respiratory/ears, nose, and throat;
gastrointestinal; genitourinary; intraocular; and intracranial.
Read codes used to deﬁne and classify bleeding events are
available at http://www.keele.ac.uk/mrr. Where the date of
the bleeding event was the same as the index date, these
bleeding events were regarded as in-hospital bleeds and,
therefore, excluded.
Follow-Up
For all analyses, patients who were discharged alive were
longitudinally followed up for a maximum of 12 months for
records of bleeding consultations after hospital discharge for
ACS. Follow-up started from the index date (date of hospital
discharge) until earliest of ﬁrst bleeding event or date patient
ceased contributing to CPRD because of death or transfer out
of practice or practice leaving CPRD or the end of 12 months
from the index date of hospital discharge or the date of last
data collection at the time of data request.
Statistical Analysis
All analyses were based on a ﬁrst bleeding event for a patient
after hospital discharge for ACS. Baseline sociodemographic
characteristics, comorbidities, in-hospital procedures, and
pharmacological characteristics were descriptively compared
between those who did and those who did not experience
bleeding events within the ﬁrst 12 months after hospital
discharge. Continuous variables are presented as mean and
SD or median and interquartile range, and they were
compared using Student t test or Mann-Whitney test, as
appropriate. Categorical variables are presented as frequen-
cies and percentages, and they were compared using v2 test.
Figure 1. Flow diagram describing the steps involved in identifying the study population. ACS indicates
acute coronary syndrome; CPRD, Clinical Practice Research Datalink; HES, Hospital Episode Statistics;
ONS, Ofﬁce for National Statistics mortality data.
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Fine and Gray competing risk regression model27 was used
to determine univariable and multivariable associations
between the outcomes of bleeding (and of each type of
bleeding event) with potential predictors, accounting for death
as a competing event, and reported using sub–hazard ratios
(sHRs) with their corresponding 95% CIs. Death from a non-
bleeding cause was selected as a competing event because of
the older age of the cohort and will prevent a bleeding event
occurring. All multivariable associations were adjusted for
year of index hospital discharge, geographic region, and all
Figure 2. Crude incidence rates (per 1000 person-years) of bleeding within 12 months after hospital
discharge by time from the date of hospital discharge.
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other potential predictors. Robust variance estimators were
used to account for clustering within general practices.
Fractional polynomials were used to determine the functional
form of age, and a plot of age against rates of bleeding (per
1000 person-years) was then used to create cut points in
categorizing age when the linear form was not appropriate.
The proportional hazard assumption was examined by
inclusion of time-by-covariate interactions in the ﬁnal
models.
To address missing data in smoking status and body mass
index, multiple imputation (10 imputations) was performed.28
To assess the impact of missing data, a sensitivity analysis
was performed (for the outcome of all bleeds) in which only
patients with complete data on all variables were included
(complete case analysis). Results of the complete case
analysis were compared with those from the imputed data
analysis. Only results of analyses on the imputed data sets are
presented here. Results of the complete case analysis are
reported in Data S1. As a subgroup analysis, the predictors for
bleeding in patients managed with percutaneous coronary
intervention (PCI) during the ACS hospitalization were deter-
mined. All comparisons were 2 tailed, and P<0.05 was
considered statistically signiﬁcant. All analyses were per-
formed using Stata, version 14.2.
Results
Incidence, Timing, and Types of Postdischarge
Bleeding Events
Figure 1 shows the number of patients included in the study,
with exclusions. A total of 27 660 patients constituted the
study population, of which 3620 (13%) experienced 5041
bleeding events over a median follow-up of 365 days
(interquartile range, 246–365 days) after hospital discharge.
Of the 3620 patients with bleeding events, 947 (26%) had
multiple bleeding events within the ﬁrst 12 months of hospital
discharge. Of those with multiple bleeding events, 69%
(n=654) had 2 bleeding events, 21% (n=197) had 3 bleeding
events, and 10% (n=96) had ≥4 bleeding events after hospital
discharge. The median time to a ﬁrst bleeding event within the
ﬁrst 12 months was 123 days (interquartile range, 45–223
days). The incidence of bleeding was 162/1000 person-years
(95% CI, 157–167/1000 person-years), and bleeding events
occurred more frequently in the ﬁrst 30 days after hospital
discharge (Figure 2).
Table 1 shows the incidence, timing, and types of bleeding
events (based on ﬁrst bleed). Bruising was the most common
(26% of all ﬁrst bleeds), followed by gastrointestinal bleeds
(20%). The incidence was highest for bruising (42/1000
person-years) and lowest for intracranial bleeding events (3/
1000 person-years).
Baseline Characteristics
Table 2 summarizes the baseline characteristics of those who
experienced bleeding complications and those who did not
within the ﬁrst 12 months after hospital discharge for ACS.
Patients who experienced bleeding complications after hos-
pital discharge were, on average, older (mean, 72 versus 70
years) and more commonly ex-smokers with higher preva-
lence of baseline hypertension, chronic obstructive pulmonary
disease (COPD), anemia, hyperlipidemia, chronic kidney
disease, history of bleeding complications (in 2 years before
the index date), and a lower level of hemoglobin. Those who
experienced bleeding events were also more commonly
treated with oral anticoagulants after discharge. The baseline
characteristics of the study population, stratiﬁed by site-
speciﬁc bleeding events, are summarized in Table S2. Patients
who experienced bruising were, on average, younger (age,
70 years) and more commonly women, whereas those who
experienced intracranial bleeds were mostly older (age,
76 years) with a higher prevalence of chronic kidney disease.
Predictors of Bleeding Events
Age violated the linearity assumption of the competing risk
model and was, therefore, categorized. Predictors that
violated the proportional hazard assumption were included
in the relevant models as time-dependent coefﬁcients. The
change in risk of bleeding for each predictor that interacted
with time, and was signiﬁcantly associated with bleeding, is
reported in Table S3 at 2 time points (at 30 and at 365 days)
after hospital discharge.
The crude and adjusted associations of each predictor with
bleeding are presented in Table S4. Figure 3 presents the
Table 1. Incidence and Timing of Each (First) Bleeding Event
Within 12 Months After Hospital Discharge
Site of Bleed
Bleeding
Events, No.
(% of All
First Bleeds)
Incidence Rate
(per 1000
Person-Years)
(95% CI)
Timing of
Bleed Within
12 Months,
Median (IQR), d
All bleeds 3620 (100) 162 (157–167) 123 (45–223)
Bruising 949 (26) 42 (39–44) 126 (49–212)
Gastrointestinal 705 (20) 32 (30–35) 116 (41–230)
Other
unclassified
700 (19) 32 (30–35) 118 (41–231)
Respiratory/ENT 582 (16) 27 (25–29) 128 (47–222)
Genitourinary 468 (13) 22 (20–24) 119 (41–226)
Intraocular 135 (4) 6 (5–7) 162 (52–239)
Intracranial 81 (2) 3 (3–4) 117 (42–222)
ENT indicates ears, nose, and throat; IQR, interquartile range.
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Table 2. Baseline Characteristics of the Study Population by Bleeding Events Within 12 Months After Hospital Discharge
Demographic Characteristics
Bleeding After Discharge
Bleed (n=3620) No Bleed (n=24 040) P Value
Age, meanSD, y 72.112.9 69.613.7
Age, n (%)
≤65 1079 (29.8) 9309 (38.7) <0.001
66–80 1433 (39.6) 8614 (35.8)
>80 1108 (30.6) 6117 (25.4)
Sex, n (%)
Men 2126 (58.7) 15 729 (65.4) <0.001
Women 1494 (41.3) 8311 (34.6)
BMI, n (%)
Underweight (BMI <18.50 kg/m2) 62 (2.3) 325 (1.9) 0.262
Normal weight (BMI 18.50–<25 kg/m2) 828 (31.4) 5096 (30.2)
Overweight (BMI 25–<30 kg/m2) 1031 (39.0) 6798 (40.3)
Obese (BMI ≥30 kg/m2) 720 (27.3) 4647 (27.6)
Smoking status, n (%)
Nonsmoker 1032 (34.0) 6428 (33.1) <0.001
Ex-smoker 1269 (41.8) 7432 (38.2)
Current smoker 735 (24.2) 5576 (28.7)
Comorbidities
Diabetes mellitus, n (%) 814 (22.5) 5002 (20.8) 0.021
Hypertension, n (%) 1075 (29.7) 6028 (25.1) <0.001
Heart failure, n (%) 337 (9.3) 2184 (9.1) 0.662
Cancer, n (%) 431 (11.9) 2526 (10.5) 0.011
PVD, n (%) 174 (4.8) 776 (3.2) <0.001
Stroke/TIA, n (%) 249 (6.9) 1326 (5.5) 0.001
COPD, n (%) 944 (26.1) 4616 (19.2) <0.001
Anemia, n (%) 1123 (31.0) 5535 (23.0) <0.001
Atrial fibrillation, n (%) 284 (7.8) 1450 (6.0) <0.001
Hyperlipidemia, n (%) 2499 (69.0) 15 309 (63.7) <0.001
History of bleeding, n (%) 759 (21.0) 2563 (10.7) <0.001
CKD (eGFR <60 mL/min per 1.73 m2), n (%) 1314 (36.3) 7093 (29.5) <0.001
ACS presentation, n (%)
STEMI 439 (12.1) 3193 (13.3) 0.003
NSTEMI 1452 (40.1) 8963 (37.3)
ACS not otherwise specified 1729 (47.8) 11 884 (49.4)
Hemoglobin, meanSD, g/L 13219.8 13618.7 <0.001
Diastolic blood pressure, meanSD, mm Hg 76.212.1 77.212.0 <0.001
Systolic blood pressure, meanSD, mm Hg 13719.8 13719.4 0.872
White cell count (9109/L), median (IQR) 7.4 (6.2–8.9) 7.4 (6.2–9.1) 0.305
In-hospital procedures, n (%)
Coronary angiography (only) 567 (15.7) 3693 (15.4) 0.641
Continued
DOI: 10.1161/JAHA.119.013679 Journal of the American Heart Association 6
Predictors of Site-Speciﬁc Bleeding Events Ismail et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on October 29, 2019
independent predictors for bleeding within the ﬁrst 12 months
after hospital discharge. After multivariable adjustment, age
>65 years, female sex, history of hypertension, peripheral
vascular disease (PVD), COPD, not having a history of heart
failure, history of bleeding complications, management with
PCI during the ACS hospitalization stay, use of NSAIDs, and
treatment with oral anticoagulants or single antiplatelet after
hospital discharge were independently associated with 12-
month postdischarge bleeding events. The most signiﬁcant
predictors of bleeding were baseline history of bleeding
complications (sHR, 1.88; 95% CI, 1.73–2.04), management
with oral anticoagulants versus single antiplatelet after
hospital discharge (sHR, 1.35; 95% CI, 1.17–1.55), aged
>80 years versus aged ≤65 years (sHR, 1.42; 95% CI, 1.22–
1.66), COPD (sHR, 1.29; 95% CI, 1.20–1.39), and PVD
(sHR, 1.28; 95% CI, 1.09–1.50). The increased risk of bleeding
in those managed with PCI or those aged >80 years
(compared with those aged ≤65 years) was highest immedi-
ately after hospital discharge, but then decreased with time
(Table S3).
Results of the sensitivity analysis did not reveal any
disparities in ﬁndings between the imputed data analysis and
the complete case analysis (Table S5). In the subgroup
analysis, advanced age (>80 versus age ≤65 years), female
sex, history of cancer, PVD, COPD, bleeding complications,
and use of NSAIDs were the main predictors of bleeding
events within the ﬁrst 12 months after hospital discharge in
patients managed with PCI (Figure 4). Treatment with oral
anticoagulant was also associated with an increased risk of
bleeding in patients managed with PCI, but this association
did not reach statistical signiﬁcance.
Predictors of Site-Speciﬁc Bleeding Events
Characteristics independently associated with each site-
speciﬁc bleeding event are reported in Table 3. After multi-
variable adjustment, history of bleeding complications (sHR,
2.22; 95% CI, 1.87–2.64), advanced age (>80 versus
≤65 years) (sHR, 1.29; 95% CI, 1.01–1.65), and COPD (sHR,
1.29; 95% CI, 1.08–1.55) were the independent predictors of
gastrointestinal bleeding events. Treatment with single
antiplatelet after hospital discharge was also associated with
an increased risk of gastrointestinal bleed. History of diabetes
mellitus (sHR, 1.77; 95% CI, 1.08–2.89) and bleeding
complications (sHR, 1.91; 95% CI, 1.05–3.45) were the main
predictors of intracranial bleeds after hospital discharge.
Treatment with oral anticoagulants, use of NSAIDs, history of
PVD, aged 66 to 80 years, and advanced age (>80 years)
were also associated with increased risk of intracranial bleed,
but these associations did not reach statistical signiﬁcance.
Risk factors independently associated with each site-speciﬁc
bleeding event are reported in Table 3.
Discussion
This is the ﬁrst electronic health record–based study to
examine the incidence, timing, and types of postdischarge
bleeding events and their predictors from a primary care
perspective. Our study reports that bleeding complications
after hospital discharge are common and occur in 1 in 10
patients within the ﬁrst 12 months after hospital discharge,
with bruising and gastrointestinal bleeds the most common.
We report that the median time to a ﬁrst bleeding event was
Table 2. Continued
Demographic Characteristics
Bleeding After Discharge
Bleed (n=3620) No Bleed (n=24 040) P Value
PCI 1201 (33.2) 8484 (35.3) 0.013
Drug therapy, n (%)
Baseline NSAIDs 500 (13.8) 2983 (12.4) 0.018
Baseline SSRIs 320 (8.8) 1771 (7.4) 0.002
Discharge antithrombotic
Single antiplatelet 908 (25.1) 6046 (25.1) <0.001
Dual antiplatelet 2151 (59.4) 14 319 (59.6)
Oral anticoagulant 276 (7.6) 1283 (5.3)
No record 285 (7.9) 2392 (10.0)
Number of patients with missing data: smoking (n=5188), BMI (n=8153), hemoglobin (n=8702), diastolic and systolic blood pressure (n=9592), white cell count (n=8914). ACS indicates
acute coronary syndrome; BMI, body mass index; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular ﬁltration rate; IQR, interquartile
range; NSTEMI, non ST-segment–elevation myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; SSRI, selective serotonin reuptake inhibitor;
STEMI, ST-segment–elevation myocardial infarction; TIA, transient ischemic attack.
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123 days, with bleeding events more commonly occurring in
the ﬁrst 30 days after hospital discharge. Our analysis found
that history of bleeding complications in 2 years before
hospital discharge, management with oral anticoagulants
after hospital discharge, COPD, PVD, and advanced age
(>80 years) were the major predictors of bleeding complica-
tions in the ﬁrst 12 months after hospital discharge. Predic-
tors for postdischarge bleeding varied, depending on the
anatomic site of the bleeding event. We report that charac-
teristics, such as COPD, use of NSAIDs, and history of cancer,
which have not been previously examined in a population with
ACS, may carry greater risk for bleeding complications after
hospital discharge.
The results of our study add granularity to the growing
body of literature evaluating the risk of bleeding complications
after hospital discharge. The ﬁnding that 13% of patients had
experienced bleeding complications in the year after dis-
charge was higher than those reported in the ADAPT-DES
(Assessment of Dual Antiplatelet Therapy With Drug-Eluting
Stents) study29 and other previous studies in the postdis-
charge setting (range, 2.5%–7.9%).30,31 This higher incidence
likely reﬂects differences in the deﬁnition of bleeding used, as
the emphasis in previous studies has been on major bleeding
events. The higher incidence may also be because of the
primary care population with elderly multimorbid patients,
which were mostly excluded from randomized controlled
trials. Our study did not capture bleeding events that are not
actionable and did not cause patients to seek medical advice.
This highlights that the actual incidence of postdischarge
bleeding events may be higher than what we have reported.
Our study and previous studies25,26 have identiﬁed the ﬁrst
30 days of hospital discharge as the period for greater
vulnerability for these bleeding complications and highlight
the time when resources can be better used to improve
longer-term patient prognosis, such as by personalization of
antithrombotic drugs at the time of hospital discharge. We
Figure 3. Characteristics associated with bleeding events within 12 months after hospital discharge for acute
coronary syndrome. *Included as time-dependent coefﬁcient: estimated sub–hazard ratio (sHR) at day of hospital
discharge but decreases with time after discharge. †Included as time-dependent coefﬁcient: estimated sHR at day of
hospital discharge but increases with time after discharge. COPD indicates chronic obstructive pulmonary disease;
Dapt, dual antiplatelet; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease.
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report that bruising was the most common type of bleeding
complication after hospital discharge. These types of bleeding
events, which have mostly been neglected in previous studies,
can be detrimental. Bruising may impact on patient quality of
life, leading to discontinuation of antithrombotic therapy,
which can have indirect adverse consequences.32,33
We found that the predictors (eg, age, hypertension, PVD,
history of bleeding, management with PCI during ACS
hospitalization, and use of oral anticoagulants)8–10,14 for in-
hospital bleeding have some overlap with those for postdis-
charge bleeding events. But characteristics, such as those
related to ACS presentation, may carry less impact on risk of
postdischarge bleeding. Although there was some overlap
between the predictors for in-hospital and postdischarge
bleeding events, the predictors for site-speciﬁc bleeds vary,
depending on the anatomic site of the bleeding event.
A novel ﬁnding of this study in reviewing the predictors of
site-speciﬁc bleeding complications was that, although char-
acteristics such as advanced age (>80 years) and prior
history of bleeding complications were predictive of all types
of bleeding events (except bruising), some predictors were
more associated with certain types of bleeds. We found that
the female sex was only predictive of nuisance bruising, and
not major bleeds (eg, gastrointestinal or intracranial bleeds),
contrary to that reported by in-hospital studies.8,9,14 This
ﬁnding is consistent with most studies of bleeding in the
postdischarge setting, which showed a lack of association
between female sex and major bleeding events.21,34
Another novel ﬁnding from our analysis was that COPD is a
strong predictor of bruising, respiratory, gastrointestinal, and
genitourinary bleeding events. Most contemporary studies in
the ACS setting have either not included COPD as a potential
predictor or not recorded its diagnosis. Our ﬁnding on the
effect of COPD on the occurrence of bleeding suggests that
COPD should be taken into account when evaluating future
risk of bleeding complications. COPD is characterized by local
and systemic inﬂammation.35 Patients with COPD are
exposed to oxidative stress via chronic hypoxia and increased
release of reactive oxygen species by leukocytes.36 This
damages gastric mucosa37 and may predispose to peptic
ulcer bleeds.38 Patients with COPD are often treated with
steroids to control lung inﬂammation. Steroids may delay
peptic ulcer healing,39 thus increasing the risk of perforation
and bleeding complications.40 The association of COPD with
bleeding events should be explored further to conﬁrm the
result of our study.
Our study found cancer to be a strong predictor of
respiratory bleeding events and a modest nonsigniﬁcant
increased risk of gastrointestinal bleeds. Malignancy has been
an exclusion criterion in previous studies, such as
the CRUSADE (Can rapid risk stratiﬁcation of unstable angina
patients suppress adverse outcomes with early
Figure 4. Characteristics associated with bleeding events within 12 months after hospital discharge for acute
coronary syndrome in patients managed with percutaneous coronary intervention. †Included as time-dependent
coefﬁcient: estimated sub–hazard ratio (sHR) at day of hospital discharge but increases with time after
discharge. COPD indicates chronic obstructive pulmonary disease; Dapt, dual antiplatelet; PVD, peripheral
vascular disease.
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Table 3. Characteristics Independently Associated With Site-Speciﬁc Bleeding Events Within 12 Months After Hospital Discharge
for ACS
Risk Factors
Bruising
(n=949)*
Respiratory/
ENT Bleeds (n=582)*
Gastrointestinal
Bleeds (n=705)*
Genitourinary
Bleeds (n=468)*
Intraocular
Bleeds (n=135)*
Intracranial
Bleeds (n=81)*
Demographics
Age, y
≤65 1.00 1.00 1.00 1.00 1.00 1.00
66–80 0.98 (0.84–1.14) 1.27 (1.01–1.60)† 1.05 (0.86–1.29) 1.37 (1.05–1.79)† 2.02 (1.26–3.25)† 1.81 (0.86–3.83)
>80 0.81 (0.65–1.03) 1.60 (1.21–2.12)† 1.29 (1.01–1.65)† 1.65 (1.21–2.24)† 1.49 (0.81–2.75) 2.31 (0.92–5.79)
Women 2.11 (1.85–2.41)† 0.94 (0.79–1.12) 0.97 (0.82–1.13) 0.84 (0.67–1.06) 0.78 (0.55–1.11) 1.13 (0.74–1.73)
BMI, kg/m2
Normal weight
(18.50–<25)
1.00 1.00 1.00 1.00 1.00 1.00
Underweight
(<18.50)
1.16 (0.73–1.87) 2.02 (0.89–4.58)‡ 0.94 (0.49–1.79) 0.73 (0.26–2.04) 0.93 (0.23–3.70) 1.14 (0.34–3.80)
Overweight
(25–<30)
1.10 (0.93–1.31) 0.93 (0.75–1.16) 1.23 (0.84–1.81)‡ 0.95 (0.74–1.22) 0.74 (0.45–1.21) 0.59 (0.34–1.02)
Obese (≥30) 0.99 (0.81–1.21) 0.91 (0.71–1.17) 1.03 (0.82–1.31) 1.12 (0.82–1.51) 0.81 (0.49–1.33) 0.42 (0.20–0.88)†
Smoking status
Nonsmoker 1.00 1.00 1.00 1.00 1.00 1.00
Ex-smoker 0.97 (0.80–1.17) 1.13 (0.90–1.43) 0.95 (0.77–1.17) 1.10 (0.88–1.38) 1.07 (0.71–1.61) 1.15 (0.69–1.92)
Current smoker 0.87 (0.71–1.07) 0.96 (0.74–1.24) 0.99 (0.79–1.25) 0.97 (0.72–1.30) 0.94 (0.52–1.68) 0.79 (0.37–1.68)
Comorbidities
Diabetes mellitus 0.73 (0.61–0.88)† 0.91 (0.73–1.13) 0.92 (0.77–1.10) 0.96 (0.76–1.19) 1.10 (0.73–1.65) 1.77 (1.08–2.89)†
Hypertension 1.02 (0.88–1.18) 1.43 (1.20–1.72)† 1.11 (0.94–1.31) 0.98 (0.79–1.22) 1.43 (1.02–2.02)† 1.01 (0.62–1.66)
Heart failure 0.75 (0.59–0.96)† 1.09 (0.82–1.43) 0.87 (0.67–1.13) 0.80 (0.57–1.11) 1.10 (0.42–2.91)‡ 0.36 (0.13–0.97)†
Cancer 0.97 (0.79–1.19) 1.86 (1.26–2.74)†,‡ 1.17 (0.94–1.46) 1.10 (0.84–1.45) 0.77 (0.43–1.37) 0.78 (0.38–1.63)
PVD 1.20 (0.82–1.76) 1.30 (0.90–1.87) 1.06 (0.72–1.54) 1.33 (0.85–2.08) 1.03 (0.46–2.30) 1.31 (0.49–3.55)
COPD 1.21 (1.04–1.40)† 1.66 (1.36–2.01)† 1.29 (1.08–1.55)† 1.26 (1.01–1.58)† 1.02 (0.64–1.63) 1.11 (0.64–1.93)
CKD (eGFR <60 mL/
min per 1.73 m2)
1.10 (0.93–1.31) 0.81 (0.66–1.00) 1.12 (0.95–1.33) 0.93 (0.73–1.18) 1.71 (1.11–2.65)† 1.06 (0.61–1.84)
Hyperlipidemia 1.09 (0.93–1.26) 1.15 (0.94–1.40) 0.94 (0.73–1.22)§ 1.00 (0.83–1.20) 1.32 (0.88–1.95) 0.74 (0.45–1.23)
History of bleeding 1.11 (0.79–1.56)§ 2.06 (1.70–2.49)† 2.22 (1.87–2.64)† 2.79 (2.26–3.44)† 2.11 (1.34–3.34)† 1.91 (1.05–3.45)†
ACS presentation
STEMI 1.00 1.00 1.00 1.00 1.00 1.00
NSTEMI 1.13 (0.92–1.39) 0.89 (0.69–1.15) 0.82 (0.65–1.04) 1.18 (0.85–1.64) 1.07 (0.59–1.93) 0.75 (0.40–1.42)
Not otherwise
specified
1.01 (0.83–1.22) 0.85 (0.65–1.11) 0.83 (0.65–1.05) 1.21 (0.89–1.63) 1.09 (0.62–1.94) 0.69 (0.37–1.30)
In-hospital procedure
PCI 1.24 (1.06–1.44)† 1.87 (1.37–2.54)†,‡ 1.04 (0.87–1.26) 1.03 (0.81–1.30) 1.20 (0.77–1.86) 1.01 (0.58–1.77)
Drug therapy
Baseline NSAIDs 1.06 (0.89–1.27) 1.29 (1.04–1.59)† 1.12 (0.89–1.42) 1.26 (0.95–1.66) 0.96 (0.58–1.59) 1.95 (0.71–5.32)‡
Baseline SSRIs 1.23 (1.00–1.50)† 0.93 (0.68–1.28) 1.12 (0.88–1.42) 1.23 (0.90–1.68) 1.64 (0.97–2.77) 1.03 (0.48–2.19)
Single antiplatelet 1.00 1.00 1.00 1.00 1.00 1.00
Dual antiplatelet 1.34 (1.14–1.57)† 0.75 (0.54–1.04)§ 0.67 (0.49–0.91)†,§ 1.17 (0.93–1.48) 2.10 (1.27–3.45)† 1.03 (0.62–1.72)
Continued
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implementation of the ACC/AHA guidelines), DAPT (Dual
antiplatelet therapy study), and Trilogy-ACS (Targeted platelet
inhibition to clarify the optimal strategy to medically manage
acute coronary syndromes).8,12,13 Cancers that are systemic,
such as those emanating from the gastroesophageal tract, are
more likely to increase bleeding complications. Therefore,
thoughtful consideration should be given to this group of
patients when deciding on secondary management strategy
after ACS. We found dual antiplatelet therapy to be associated
with a decreased risk of gastrointestinal bleed in the
immediate period after hospital discharge. The decreased
risk of gastrointestinal bleed with dual antiplatelet may be
caused by an element of confounding by indication, with
patients deemed to be at highest risk for this type of bleed
only prescribed single antiplatelet at the time of hospital
discharge.
We found treatment with oral anticoagulants to be
associated with higher risk of respiratory, genitourinary, and
intraocular bleeding events after hospital discharge. Of
patients in our study, 6% were prescribed oral anticoagulants,
with most (92%) given warfarin at discharge. Replacing
warfarin with the newer oral anticoagulants that have a more
favorable safety proﬁle may mitigate the bleeding complica-
tions in this group of patients.41,42 In patients managed with
PCI, who have an indication for oral anticoagulants, such as
those with atrial ﬁbrillation who are at increased risk of
stroke, secondary management involving an antiplatelet (eg,
clopidogrel) and a newer oral anticoagulant, as stipulated in
the updated American Heart Association guideline for the
management of patients with atrial ﬁbrillation, will reduce the
risk of late bleeding events.43 For patients prescribed triple
therapy (aspirin plus P2Y12 inhibitor plus an oral anticoag-
ulant), the duration of this therapy should be minimized to a
period of 4 to 6 weeks and dual therapy (a P2Y12 inhibitor
plus an oral anticoagulant) should be considered thereafter,43
to minimize the risk of bleeding.
The ﬁndings of this study should be interpreted in light of
some limitations. First, bleeding events were not indepen-
dently adjudicated. The observational design of the study
does not preclude residual confounding. The deﬁnition for
bleeding did not include laboratory parameters, such as
decrease in hemoglobin measurements and/or receipt of
blood transfusion. Classifying bleeding on the basis of severity
(major and minor) was, therefore, not possible. The study was
not adequately powered to examine the independent predic-
tors of some types of bleeding events, such as intracranial
and intraocular bleeds that occurred relatively rarely. Thus,
ﬁndings in relation to these bleeding events should be viewed
as exploratory. Reporting bias may be a cause for concern in
our study because not all patients who experience minor and
nuisance bleeding events (eg, nose bleeds and bruising) will
seek medical advice. Therefore, the incidence of bleeding is
likely to have been underreported, although more signiﬁcant
bleeds may have been likely recorded. Prasugrel, ticagrelor,
and the newer oral anticoagulants became available during
the study period, but most patients (90%) were mostly treated
with aspirin, clopidogrel, or warfarin after discharge. We
restricted our study to people in England. Thus, the gener-
alizability of our results outside of England is unclear. Finally,
we were unable to examine the impact of dosing and duration
of discharge antithrombotic drugs and those of emerging risk
factors, such as frailty and genetic factors, on risk of future
bleeding events.
In summary, bleeding complications after hospital dis-
charge are common and occur more frequently in the ﬁrst
30 days after hospital discharge. Patients who experience
these bleeding events have distinct baseline characteristics.
These characteristics differ, depending on the anatomic site
of the bleeding event. Identiﬁcation of these characteristics is
an important step toward developing a real-world risk
stratiﬁcation tool that can facilitate a more patient-centered
approach in deciding on favorable combination and duration
of secondary antithrombotic therapy after ACS.
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Clinical Practice Research Datalink (CPRD) 
The CPRD is a primary care database containing individual patient’s demographic information, 
tests, clinical events (such as diagnosis), referrals, prescriptions, and immunisations from a 
subset of UK general practices that had consented to periodically provide patient data for 
research purposes (1). In the UK, general practices are the first point of contact for non-
emergency health related issues, and diagnoses during these encounters are electronically 
recorded using the Read coding system. A subset of practices in England (75% of English 
practices, 55% of all UK practices) contributing to CPRD have consented to their primary care 
records being linked to HES and ONS (1). CPRD is generally representative of the UK 
population on age, gender and ethnicity (1, 2). 
Data S1.
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Table S1. Candidate predictors of bleeding for model development. 
Socio-demographic characteristics (recorded in the 2 years prior to index 
date except BMI which was recorded until 30 days after index date) 
Advanced age 
Female sex 
Body mass index* (BMI) 
History of smoking† 
Comorbidities (recorded in the 2 years prior to index date) 
History of diabetes 
History of hypertension 
History of heart failure 
History of cancer 
History of peripheral vascular disease 
History of chronic obstructive pulmonary disease (COPD) 
History of renal insufficiency‡ 
Hyperlipidemia 
History of bleeding 
STEMI at presentation 
NSTEMI at presentation 
In-hospital procedure 
Percutaneous coronary intervention (PCI) at index ACS hospitalisation 
Pharmacological characteristics 
NSAID prescription within 6 months prior to hospital discharge 
SSRI prescription within 6 months prior to hospital discharge 
Discharge antithrombotic therapy§ (whether single antiplatelet (SAPT), 
dual antiplatelet (DAPT) or receipt of oral anticoagulant) 
D
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*BMI was classified into underweight, normal weight, overweight, and obese following the WHO
classification. 
†Smoking was defined as non-smoker, ex-smoker and current smoker. 
‡Renal insufficiency was defined by Estimated Glomerular Filtration Rate (eGFR), calculated using 
the Chronic Kidney Disease Epidemiology Collaboration Equation (CKD-EPI) as eGFR < 60 mL/min 
per 1.73 m2 (3). 
§Discharge antithrombotic therapy was classified into single antiplatelet therapy (a prescription record
for one of aspirin, clopidogrel, prasugrel or ticagrelor), dual antiplatelet therapy (a prescription record 
for aspirin and one of clopidogrel, prasugrel or ticagrelor) and receipt of oral anticoagulation (a 
prescription record for one of warfarin, apixaban, rivaroxaban or dabigatran, with or without 
concomitant antiplatelets) all measured within 90 days post index date in the patient’s primary care 
record.  
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Table S2. Baseline characteristics of the study population by site of bleeding events within the first 12 months after hospital discharge. 
Demographic characteristics 
No Bleeds 
(n = 24040) 
Bruising 
(n = 949) 
Respiratory/ent 
bleeds 
 (n = 582) 
Gastrointestinal 
bleeds 
(n = 705) 
Genitourinary 
bleeds 
 (n = 468) 
Intraocular 
bleeds 
 (n = 135) 
Intracranial 
bleeds 
 (n = 81) 
Age (Mean ± SD) 69.6 ± 13.7 69.6 ± 13.0 72.6 ± 12.7 71.9 ± 13.6 72.1 ± 13.5 72.4 ± 10.9 76.3 ± 11.8 
Age (n, %) 
≤ 65 9309 (38.7) 348 (36.7) 167 (28.8) 225 (31.9) 134 (28.6) 29 (21.5) 15 (18.1) 
66 - 80 8614 (35.8) 367 (38.8) 228 (39.3) 256 (36.3) 185 (39.5) 68 (50.4) 31 (37.3) 
> 80 6117 (25.4) 232 (24.5) 185 (31.9) 224 (31.8) 149 (31.8) 38 (28.1) 37 (44.6) 
15729 (65.4) 455 (48.0) 373 (64.3) 445 (63.1) 313 (66.9) 89 (65.9) 46 (55.4) 
8311 (34.6) 492 (52.0) 207 (35.7) 260 (36.9) 155 (33.1) 46 (34.1) 37 (44.6) 
Sex (n, %) 
Male 
Female 
BMI (kg/m2) (n, %) 
Underweight (BMI < 18.50) 325 (1.9) 20 (2.9) 12 (2.9) 9 (1.8) 5 (1.5) * * 
Normal weight (BMI 18.50 to < 25) 5096 (30.2) 201 (29.4) 133 (31.7) 154 (30.0) 101 (30.4) 36 (35.3) 30 (49.2) 
Overweight (BMI 25 to < 30) 6798 (40.3) 286 (41.8) 163 (38.9) 202 (39.4) 123 (37.0) 36 (35.3) 20 (32.8) 
Obese (BMI ≥ 30) 4647 (27.6) 177 (25.9) 111 (26.5) 148 (28.8) 103 (31.0) 28 (27.5) 8 (13.1) 
Smoking Status (n, %) 
Non smoker 6428 (33.1) 288 (36.5) 152 (31.4) 201 (34.0) 126 (32.4) 39 (34.8) 24 (37.5) 
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Ex-smoker 7432 (38.2) 288 (36.5) 220 (45.5) 235 (39.7) 175 (45.0) 51 (45.5) 29 (45.3) 
Current smoker 5576 (28.7) 212 (26.9) 112 (23.1) 156 (26.4) 88 (22.6) 22 (19.6) 11 (17.2) 
Comorbidities 
Diabetes (n, %) 5002 (20.8) 157 (16.6) 121 (20.9) 155 (22.0) 104 (22.2) 35 (25.9) 24 (28.9) 
Hypertension (n, %) 6028 (25.1) 253 (26.7) 199 (34.3) 206 (29.2) 123 (26.3) 48 (35.6) 23 (27.7) 
Heart failure (n, %) 2184 (9.1) 65 (6.9) 66 (11.4) 67 (9.5) 41 (8.8) 8 (5.9) * 
Cancer (n, %) 2526 (10.5) 94 (9.9) 78 (13.4) 95 (13.5) 61 (13.0) 13 (9.6) 8 (9.6) 
PVD (n, %) 776 (3.2) 35 (3.7) 29 (5.0) 28 (4.0) 23 (4.9) 6 (4.4) * 
Stroke/TIA (n, %) 1326 (5.5) 47 (5.0) 43 (7.4) 46 (6.5) 37 (7.9) 7 (5.2) 12 (14.5) 
COPD (n, %) 4616 (19.2) 216 (22.8) 177 (30.5) 182 (25.8) 121 (25.9) 30 (22.2) 20 (24.1) 
Anemia (n, %) 5535 (23.0) 187 (19.7) 168 (29.0) 220 (31.2) 136 (29.1) 40 (29.6) 23 (27.7) 
Atrial fibrillation (n, %) 1450 (6.0) 60 (6.3) 51 (8.8) 49 (7.0) 45 (9.6) 9 (6.7) 15 (18.1) 
Hyperlipidemia (n, %) 15309 (63.7) 624 (65.9) 403 (69.5) 497 (70.5) 313 (66.9) 101 (74.8) 51 (61.4) 
History of bleeding (n, %) 2563 (10.7) 137 (14.5) 126 (21.7) 162 (23.0) 126 (26.9) 30 (22.2) 19 (22.9) 
CKD (eGFR < 60 mL/min/1.73 m2 (n, 
%)) 
7093 (29.5) 304 (32.1) 187 (32.2) 258 (36.6) 158 (33.8) 63 (46.7) 35 (42.2) 
ACS presentation (n, %) 
STEMI 3193 (13.3) 122 (12.9) 81 (14.0) 103 (14.6) 50 (10.7) 16 (11.9) 12 (14.5) 
NSTEMI 8963 (37.3) 368 (38.9) 224 (38.6) 271 (38.4) 184 (39.3) 53 (39.3) 34 (41.0) 
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ACS Not otherwise specified 11884 (49.4) 457 (48.3) 275 (47.4) 331 (47.0) 234 (50.0) 66 (48.9) 37 (44.6) 
Hemoglobin (g/L (Mean ± SD)) 136 ± 18.7 136 ± 17.6 133 ± 21.2 133 ± 20.5 133 ± 19.0 134 ± 19.0 130 ± 23.5 
Diastolic (mm Hg (Mean ± SD)) 77.2 ± 12.0 77.4 ± 11.7 75.9 ± 11.6 76.9 ± 12.2 75.4 ± 12.0 75.3 ± 10.9 78.6 ± 14.2 
Systolic (mm Hg (Mean ± SD)) 137 ± 19.4 137 ± 18.1 136 ± 19.1 137 ± 20.4 136 ± 20.0 136 ± 18.2 142 ± 22.7 
White cell count (x109/L (Median ± 
IQR)) 
7.4 (6.2, 9.1) 7.2 (6.1, 8.7) 7.5 (6.2, 9.1) 7.6 (6.3, 9.0) 7.5 (6.2, 9.2) 7.3 (6.0, 8.6) 7.4 (6.1, 9.8) 
In-hospital procedures 
Coronary angiography (only) (n, %) 3693 (15.4) 154 (16.3) 78 (13.4) 105 (14.9) 80 (17.1) 19 (14.1) 7 (8.4) 
PCI (n, %) 8484 (35.3) 366 (38.6) 198 (34.1) 232 (32.9) 154 (32.9) 48 (35.6) 22 (26.5) 
Drug Therapy (n, %) 
Baseline NSAIDs 2983 (12.4) 131 (13.8) 88 (15.2) 95 (13.5) 70 (15.0) 16 (11.9) 6 (7.2) 
Baseline SSRIs 1771 (7.4) 95 (10.0) 43 (7.4) 64 (9.1) 44 (9.4) 15 (11.1) 7 (8.4) 
Discharge antithrombotic 
Single antiplatelet 6046 (25.1) 211 (22.3) 153 (26.4) 181 (25.7) 113 (24.1) 21 (15.6) 19 (22.9) 
Dual antiplatelet 14319 (59.6) 649 (68.5) 339 (58.4) 394 (55.9) 275 (58.8) 87 (64.4) 40 (48.2) 
Oral anticoagulant 1283 (5.3) 51 (5.4) 54 (9.3) 46 (6.5) 40 (8.5) 17 (12.6) * 
No record 2392 (10.0) 36 (3.8) 34 (5.9) 84 (11.9) 40 (8.5) 10 (7.4) 22 26.5) 
* = frequency count is < 5, ACS = acute coronary syndrome, BMI = body mass index, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, eGFR
= estimated glomerular filtration rate, ENT = ear, nose, throat, IQR = interquartile range, MI = myocardial infarction, n = number of patients in each category, NSAID = 
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non-steroidal anti-inflammatory drugs, NSTEMI = Non ST-elevation myocardial infarction, PCI = percutaneous coronary intervention, PVD = peripheral vascular disease, 
SD = standard deviation, SSRI = selective serotonin re-uptake inhibitors, STEMI = ST-elevation myocardial infarction. 
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Table S3. The change in hazard of bleeding for each (statistically significant) predictor that was included as a time dependent coefficient in 
the competing risk model.  
Outcome Predictors 
Baseline Hazard*
(sHR (95% CI) 
Change in baseline hazard for 
each day post hospital 
discharge 
(sHR (95% CI) 
Risk of bleeding at 30 
days after hospital  
discharge† 
(sHR (95% CI) 
Risk of bleeding at 365 
days after hospital 
discharge† 
(sHR (95% CI) 
All bleed 
Age > 80 years 1.42 (1.22 to 1.66) 0.99921 (0.99839, 1.00003) 1.39 (1.16 to 1.67) 1.06 (0.67, 1.68) 
PCI 1.26 (1.11 to 1.43) 0.99907 (0.99840, 0.99974) 1.22 (1.05 to 1.41) 0.89 (0.62, 1.30) 
Dual antiplatelet 0.81 (0.72 to 0.93) 1.00211 (1.00134, 1.00289) 0.87 (0.74 to 1.01) 1.76 (1.16, 2.44) 
Respiratory/ent bleeds 
Cancer 1.86 (1.26 to 2.74) 0.99659 (0.99383, 0.99934) 1.68 (1.05 to 2.69) 0.53 (0.13, 2.20) 
PCI 1.87 (1.37 to 2.54) 0.99674 (0.99494, 0.99853) 1.69 (1.18 to 2.43) 0.57 (0.22, 1.55) 
Gastrointestinal bleeds Dual antiplatelet 0.67 (0.49 to 0.91) 1.00281 (1.00103, 1.00460) 0.73 (0.50 to 1.05) 1.86 (0.71, 4.25) 
* = Immediate hazard from day of hospital discharge, † = estimated as exponentiated ((Ln (change in baseline hazard)*time post-discharge (i.e. 30 or 365 days post-discharge)) + Ln
(baseline hazard)), ENT = ear, nose, throat, PCI = percutaneous coronary intervention.
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10 
Table S4. Characteristics associated with bleeding events within 12 months post-
hospital discharge for ACS. 
Characteristics 
Unadjusted 
Adjusted* 
Demographics 
sHR 
(95% CI) 
P-value
sHR 
(95% CI) 
P-value
Age (years) 
≤ 65 1.00 1.00 
66 - 80 
1.39 
(1.28 to 1.51) 
P<0.001 
1.20 
(1.10 to 1.31) 
P<0.001 
> 80
1.55 
(1.43 to 1.69) 
P<0.001 
1.42‡ 
(1.22 to 1.66) 
P<0.001 
Female 
1.32 
(1.23 to 1.40) 
P<0.001 
1.19 
(1.11 to 1.28) 
P<0.001 
BMI (kg/m2) 
Normal weight 
(18.50 to < 25) 
1.00 1.00 
Underweight 
(< 18.50) 
1.09 
(0.81 to 1.45) 
0.571 
1.01 
(0.76 to 1.34) 
0.963 
Overweight 
(25 to < 30) 
0.92 
(0.84 to 1.02) 
0.104 
0.96 
(0.87 to 1.06) 
0.410 
Obese 
(≥ 30) 
0.93 
(0.84 to 1.03) 
0.182 
0.95 
(0.85 to 1.06) 
0.354 
Smoking Status 
Non smoker 1.00 1.00 
Ex-smoker 
1.02 
(0.94 to 1.12) 
0.584 
1.05 
(0.96 to 1.14) 
0.329 
Current smoker 
0.82 
(0.75 to 0.91) 
P<0.001 
0.96 
(0.87 to 1.07) 
0.486 
Comorbidities 
Diabetes 1.10 0.013 0.99 0.812 
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(1.02 to 1.18) (0.91 to 1.07) 
Hypertension 
1.24 
(1.15 to 1.34) 
P<0.001 
1.13 
(1.05 to 1.21) 
0.001 
Heart failure 
1.02 
(0.91 to 1.14) 
0.703 
0.87 
(0.78 to 0.97) 
0.016 
Cancer 
1.14 
(1.04 to 1.26) 
0.006 
1.06 
(0.96 to 1.17) 
0.232 
PVD 
1.46 
(1.25 to 1.71) 
P<0.001 
1.28 
(1.09 to 1.50) 
0.003 
COPD 
1.44 
(1.34 to 1.55) 
P<0.001 
1.29 
(1.20 to 1.39) 
P<0.001 
CKD (eGFR < 60 mL/min/1.73 m2) 
1.34 
(1.25 to 1.43) 
P<0.001 
1.07 
(0.99 to 1.16) 
0.107 
Hyperlipidemia 
1.24 
(1.16 to 1.33) 
P<0.001 
0.97† 
(0.86 to 1.09) 
0.641 
History of bleeding 
2.08 
(1.92 to 2.25) 
P<0.001 
1.88 
(1.73 to 2.04) 
P<0.001 
ACS presentation 
STEMI 1.00 1.00 
NSTEMI 
1.17 
(1.06 to 1.30) 
0.002 
1.06 
(0.95 to 1.18) 
0.292 
ACS not otherwise specified 
1.04 
(0.94 to 1.16) 
0.466 
1.00 
(0.89 to 1.12) 
0.978 
In-hospital procedure 
PCI 
0.92 
(0.86 to 0.99) 
0.019 
1.26‡ 
(1.11 to 1.43) 
P<0.001 
Drug Therapy 
Baseline NSAIDs 
1.11 
(1.00 to 1.22) 
0.042 
1.13 
(1.02 to 1.25) 
0.017 
Baseline SSRIs 
1.22 
(1.09 to 1.37) 
P<0.001 
1.09 
(0.97 to 1.22) 
0.142 
Discharge antithrombotic 
Single antiplatelet 1.00 1.00 
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Dual antiplatelet 
1.00 
(0.92 to 1.08) 
0.962 
0.81† 
(0.72 to 0.93) 
0.002 
Oral anticoagulant 
1.39 
(1.21 to 1.60) 
P<0.001 
1.35 
(1.17 to 1.55) 
P<0.001 
No record 
0.90 
(0.80 to 1.03) 
0.117 
1.07‡ 
(0.88 to 1.30) 
0.469 
* = adjusted for year of hospital discharge, geographic region, general practice, and all listed characteristics in
the table,  † = included as time dependent coefficient – estimated sHR at day of hospital discharge but increases 
with time post-discharge, ‡ = included as time dependent coefficient – estimated sHR at day of hospital discharge 
but decreases with time post-discharge, 1.00 = reference category, ACS = acute coronary syndrome, BMI = body 
mass index, Bold text = indicates statistically significant predictors of  bleeding at the 5% threshold, CI = 
confidence interval, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, eGFR = 
estimated glomerular filtration rate, IQR = interquartile range, MI = myocardial infarction, n = number of 
patients in each category, NSAID = non-steroidal anti-inflammatory drugs, NSTEMI = Non ST-elevation 
myocardial infarction, PCI = percutaneous coronary intervention, PVD = peripheral vascular disease, sHR = 
subhazard ratio,  SSRI = selective serotonin re-uptake inhibitors, STEMI = ST-elevation myocardial infarction.  D
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Table S5. Characteristics independently associated with bleeding events in the imputed 
and complete case analysis.
Characteristics 
Imputed data analysis*
(n = 27660) 
Complete case analysis*
(n = 16273) 
Bleeding events (n = 3620) Bleeding events (n = 2259) 
Demographics 
sHR 
(95% CI) 
P-value
sHR 
(95% CI) 
P-value
Age (years) 
≤ 65 1.00 1.00 
66 - 80 
1.20 
(1.10 to 1.31) 
P<0.001 
1.14 
(1.02 to 1.27) 
0.019 
> 80
1.42‡ 
(1.22 to 1.66) 
P<0.001 
1.50‡
(1.22 to 1.84) 
P<0.001 
Female 
1.19 
(1.11 to 1.28) 
P<0.001 
1.14 
(1.05 to 1.25) 
0.003 
BMI (kg/m2) 
Normal weight (BMI 18.50 to < 25) 1.00 1.00 
Underweight (BMI < 18.50) 
1.01 
(0.76 to 1.34) 
0.963 
1.09 
(0.81 to 1.47) 
0.579 
Overweight (BMI 25 to < 30) 
0.96 
(0.87 to 1.06) 
0.410 
0.99 
(0.90 to 1.10) 
0.907 
Obese (BMI ≥ 30) 
0.95 
(0.85 to 1.06) 
0.354 
0.98 
(0.88 to 1.09) 
0.674 
Smoking Status 
Non smoker 1.00 1.00 
Ex-smoker 
1.05 
(0.96 to 1.14) 
0.329 
1.03 
(0.92 to 1.15) 
0.609 
Current smoker 
0.96 
(0.87 to 1.07) 
0.486 
0.92 
 (0.80 to 1.05) 
0.194 
Comorbidities 
Diabetes 
0.99 
(0.91 to 1.07) 
0.812 
1.04 
(0.96 to 1.14) 
0.341 
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Hypertension 
1.13 
(1.05 to 1.21) 
0.001 
1.11 
(1.02 to 1.22) 
0.020 
Heart failure 
0.87 
(0.78 to 0.97) 
0.016 
0.85 
(0.75 to 0.98) 
0.024 
Cancer 
1.06 
(0.96 to 1.17) 
0.232 
1.10 
(0.97 to 1.24) 
0.126 
PVD 
1.28 
(1.09 to 1.50) 
0.003 
1.33 
(1.10 to 1.61) 
0.003 
COPD 
1.29 
(1.20 to 1.39) 
P<0.001 
1.24 
(1.14 to 1.36) 
P<0.001 
CKD (eGFR < 60 mL/min/1.73 m2) 
1.07 
(0.99 to 1.16) 
0.107 
1.06 
(0.96 to 1.18) 
0.231 
Hyperlipidemia 
0.97† 
(0.86 to 1.09) 
0.641 
0.98†
(0.84 to 1.15) 
0.843 
History of bleeding 
1.88 
(1.73 to 2.04) 
P<0.001 
1.85 
(1.67 to 2.06) 
P<0.001 
ACS presentation 
STEMI 1.00 1.00 
NSTEMI 
1.06 
(0.95 to 1.18) 
0.292 
1.14 
(0.99 to 1.31) 
0.063 
Not otherwise specified 
1.00 
(0.89 to 1.12) 
0.978 
1.03 
(0.90 to 1.18) 
0.640 
In-hospital procedure 
PCI 
1.26‡ 
(1.11 to 1.43) 
P<0.001 
1.30‡
(1.10 to 1.53) 
0.002 
Drug Therapy 
Baseline NSAIDs 
1.13 
(1.02 to 1.25) 
0.017 
1.13 
(1.00 to 1.28) 
0.057 
Baseline SSRIs 
1.09 
(0.97 to 1.22) 
0.142 
1.11 
(0.96 to 1.29) 
0.146 
Discharge antithrombotic 
Single antiplatelet 1.00 1.00 
Dual antiplatelet 0.81† 0.002 0.85† 0.056 
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(0.72 to 0.93) (0.71 to 1.00) 
Oral anticoagulant 
1.35 
(1.17 to 1.55) 
P<0.001 
1.38 
(1.16 to 1.65) 
P<0.001 
No record 
1.07‡ 
(0.88 to 1.30) 
0.469 
1.12‡
(0.88 to 1.42) 
0.366 
* = adjusted for year of hospital discharge, geographic region, general practice, and all listed characteristics in 
the table,  † = included as time dependent coefficient – estimated sHR at day of hospital discharge but increases 
with time post discharge, ‡ = included as time dependent coefficient – estimated sHR at day of hospital discharge 
but decreases with time post discharge, 1.00 = reference category, ACS = acute coronary syndrome, BMI = body 
mass index, Bold text = indicates statistically significant predictors of  bleeding at the 5% threshold, CI = 
confidence interval, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, eGFR = 
estimated glomerular filtration rate, IQR = interquartile range, MI = myocardial infarction, n = number of 
patients in each category, NSAID = non-steroidal anti-inflammatory drugs, NSTEMI = Non ST-elevation 
myocardial infarction, PCI = percutaneous coronary intervention, PVD = peripheral vascular disease, sHR = 
subhazard ratio,  SSRI = selective serotonin re-uptake inhibitors, STEMI = ST-elevation myocardial infarction.  
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